eamdacademy.org-QmBl-1792216931-w603076873 1792216931 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2025 4 2 Jinwoo Park Minji Kim Seung Lee 2025 10.68159/w603076873 https://eamdacademy.org/pub/journal/3/article/w603076873 Huvila I, Anderson TD, Jansen EH, McKenzie P, Worrall A. Boundary objects in information science. J Assoc Inf Sci Technol. 2017;68(8):1807-22. Heiss L. Iterative prototypes as ‘boundary objects’: facilitating interdisciplinary collaboration of a modular hearing aid. Des J. 2020;23(6):865-83. Tharchen T, Garud R, Henn RL. Design as an interactive boundary object. J Organ Des. 2020;9(1):21. Melo S, Bishop S. Translating healthcare research evidence into practice: The role of linked boundary objects. Soc Sci Med. 2020;246:112731. Melville-Richards L, Rycroft-Malone J, Burton C, Wilkinson J. Making authentic: exploring boundary objects and bricolage in knowledge mobilisation through National Health Service-university partnerships. Evid Policy. 2020;16(4):517-39. Lunkka N, Jansson N, Mainela T, Suhonen M, Meriläinen M, Puhakka V, et al. Professional boundaries in action: Using reflective spaces for boundary work to incorporate a new healthcare role. Hum Relat. 2022;75(7):1270-97. Kislov R, Harvey G, Jones L. Boundary organising in healthcare: theoretical perspectives, empirical insights and future prospects. J Health Organ Manag. 2021;35(2):133-40. Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide–identification of problems and overcoming obstacles. Transl Med Commun. 2019;4(1):18. Austin CP. Opportunities and challenges in translational science. Clin Transl Sci. 2021;14(5):1629-47. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12(7):3049-62. Bae YH, Park K. Advanced drug delivery 2020 and beyond: Perspectives on the future. Adv Drug Deliv Rev. 2020;158:4-16. Grangeia HB, Silva C, Simoes SP, Reis MS. Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives. Eur J Pharm Biopharm. 2020;147:19-37. Csóka I, Pallagi E, Paál TL. Extension of quality-by-design concept to the early development phase of pharmaceutical R&D processes. Drug Discov Today. 2018;23(7):1340-3. Tyndall A, Du W, Breder CD. The target product profile as a tool for regulatory communication: advantageous but underused. Nat Rev Drug Discov. 2017;16(3):156. Wang T, McAuslane N, Goettsch WG, Leufkens HG, De Bruin ML. Challenges and opportunities for companies to build HTA/Payer perspectives into drug development through the use of a dynamic target product profile. Front Pharmacol. 2022;13:948161. Talabardon JN, Church JE, Okuse M, Dinboeck M, Dickinson S, Messner S, et al. Incorporating Patient Input into the Target Product Profile. Ther Innov Regul Sci. 2025;59(4):659-67. Ahluwalia K, Abernathy MJ, Beierle J, Cauchon NS, Cronin D, Gaiki S, et al. The future of CMC regulatory submissions: streamlining activities using structured content and data management. J Pharm Sci. 2022;111(5):1232-44. Zhao Y, Xiao N, Anderson K, Zhang Y. Electronic common technical document submission with analysis using R. Clin Trials. 2023;20(1):89-92. Wang Y, Zhu H, Madabushi R, Liu Q, Huang SM, Zineh I. Model‐informed drug development: current US regulatory practice and future considerations. Clin Pharmacol Ther. 2019;105(4):899-911. Marshall S, Madabushi R, Manolis E, Krudys K, Staab A, Dykstra K, et al. Model‐informed drug discovery and development: current industry good practice and regulatory expectations and future perspectives. CPT Pharmacometrics Syst Pharmacol. 2019;8(2):87-96. Madabushi R, Seo P, Zhao L, Tegenge M, Zhu H. Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making. Pharm Res. 2022;39(8):1669-80. Marshall S, Ahamadi M, Chien J, Iwata D, Farkas P, Filipe A, et al. Model-informed drug development: steps toward harmonized guidance. Clin Pharmacol Ther. 2023;114(5):954-9. Xiong Y, Samtani MN, Ouellet D. Applications of pharmacometrics in drug development. Adv Drug Deliv Rev. 2025;217:115503. Wang Y, Ji J, Yao Y, Nie J, Xie F, Xie Y, et al. Current status and challenges of model-informed drug discovery and development in China. Adv Drug Deliv Rev. 2024;214:115459. Aguilera-Cobos L, Rosario-Lozano MP, Ponce-Polo A, Blasco-Amaro JA, Epstein D. Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: Umbrella review. Health Policy. 2022;126(12):1248-55. Morel T, Schroeder K, Cleanthous S, Andrejack J, Blavat G, Brooks W, et al. The value of co-creating a clinical outcome assessment strategy for clinical trial research: process and lessons learnt. Res Involv Engagem. 2023;9(1):98.